Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study

M. Dreyling
M. L. Wang
S. Rule
P. Martin
A. Goy
R. Auer
B. S. Kahl
W. Jurczak
R. H. Advani
J. E. Romaguera
M. E. Williams
J. C. Barrientos
E. Chmielowska
J. Radford
S. Stilgenbauer
W. W. Jedrzejczak
P. Johnson
S. E. Spurgeon
L. Zhang
L. Baher
M. Cheng
D. M. Beaupre
K. A. Blum

Abstract